Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized,placebo-controlled trial 期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized,placebo-controlled trial

摘要：
本文献已被 ScienceDirect 等数据库收录！